U.S. markets close in 3 hours 56 minutes
  • S&P 500

    3,428.72
    -6.84 (-0.20%)
     
  • Dow 30

    28,157.35
    -53.47 (-0.19%)
     
  • Nasdaq

    11,424.78
    -59.91 (-0.52%)
     
  • Russell 2000

    1,617.74
    +13.96 (+0.87%)
     
  • Crude Oil

    40.82
    +0.79 (+1.97%)
     
  • Gold

    1,901.70
    -27.80 (-1.44%)
     
  • Silver

    24.64
    -0.61 (-2.40%)
     
  • EUR/USD

    1.1826
    -0.0041 (-0.34%)
     
  • 10-Yr Bond

    0.8500
    +0.0340 (+4.17%)
     
  • GBP/USD

    1.3085
    -0.0058 (-0.44%)
     
  • USD/JPY

    104.8720
    +0.3120 (+0.30%)
     
  • BTC-USD

    12,937.86
    +1,880.85 (+17.01%)
     
  • CMC Crypto 200

    261.12
    +5.02 (+1.96%)
     
  • FTSE 100

    5,785.65
    +9.15 (+0.16%)
     
  • Nikkei 225

    23,474.27
    -165.19 (-0.70%)
     

Glaukos Announces Presentation Cancellation at the William Blair 40th Annual Growth Stock Conference

·1 min read

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that in light of the company’s offering of its 2.75% Convertible Senior Notes due 2027, which is expected to close on June 11, 2020, subject to customary closing conditions, management will no longer be participating in its previously announced virtual fireside presentation and associated webcast at the William Blair 40th Annual Growth Stock Conference, previously scheduled for Wednesday, June 10, 2020, at 3:20 p.m. CDT. Management will continue to participate in the conference’s other investor forums.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and launched its next-generation iStent inject® device in the United States in September 2018. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005834/en/

Contacts

Chris Lewis
Director, Investor Relations, Corporate Strategy & Development
(949) 481-0510
clewis@glaukos.com